Table 3 Health state utility values by treatment line, health state and instrument

 Nafees 2016 [68]

Metastatic NSCLC^b

PD vs BL state

0.095

TTO

N/A

Patients (but not NSCLC patients) from the general public in UK, Australia, France, China, S. Korea, Taiwan

No

RES no side effects vs BL

0.773

SDis no side effects vs BL

0.460

 Chevalier 2013^c [38]

Advanced/metastatic NSCLC

1 L PF

0.69 (0.26)

EQ-5D

French (TTO)

Stage I–Stage III/IV PF and PD

Meets HAS requirements

1 L PD

0.61 (0.24)

 Chouaid 2013 [39]

Advanced/metastatic NSCLC

1 L PF

0.71 (0.24) (95% CI, 0.67–0.76)

EQ-5D-3 L

UK

At time of advanced diagnosis, mean age 64.8 years

Adenocarcinoma: 65.2%

Large-cell carcinoma: 6.8%

SQ cell carcinoma: 17.1%

Other: 9.9%

Clinical stage at time of survey:

IIIb: 17.9%

IV: 82.1%

Meets NICE requirements

69.31 (18.33) (95% CI, 65.9–72.8)

EQ-5D VAS

N/A

No

1 L PD

0.67 (0.2) (95% CI 0.59–0.75)

EQ-5D-3 L

UK

Meets NICE requirements

58.67 (17.4) (95% CI 51.3–66.0)

EQ-5D VAS

N/A

No

 Iyer 2013 [46]

Advanced/metastatic NSCLC

France, Germany 1 L

0.63 (0.31)

EQ-5D

UK1

Patients with:

Adenocarcinoma: 56.3%

Large-cell carcinoma: 11.8%

SQ cell carcinoma: 29.3%

Other: 2.5%

Stage IIIb: 15.4%

Stage: IV 84.6%

Meets NICE requirement

60.8 (19.9)

EQ-5D VAS

N/A

No

 Iyer 2013 [46]

Advanced/metastatic NSCLC

France, Germany 1 L/2 L

0.58 (0.35)

EQ-5D

UK

Patients with:

Adenocarcinoma: 56.3%

Large-cell carcinoma: 11.8%

SQ cell carcinoma: 29.3%

Other: 2.5%

Stage IIIb: 15.4%

Stage: IV 84.6%

Meets NICE and SMC requirements

France, 1 L/2 L

0.57 (0.41)

Germany, 1 L/2 L

0.59 (0.31)

France, Germany 1 L/2 L

58.0 (19.9)

EQ-5D VAS

No

France, 1 L/2 L

57.1 (21.1)

Germany, 1 L/2 L

58.6 (19.1)

 Blackhall 2014 [41]

Advanced/metastatic ALK+ NSCLC

2 L BL CRZ

0.73 (0.24)

EQ-5D-3 L

NR

Multinational patients, locally advanced/metastatic ALK+ NSCLC, 2 L

Unclear as tariff NR

2 L BL chemotherapy (PEM or DOC)

0.70 (0.26)

2 L BL PEM

0.73 (0.24)

2 L BL DOC

0.67 (0.29)

2 L on CRZ

0.82 (SE, 0.01)

(95% CI, 0.79–0.85)

2 L on Chemotherapy

0.73 (SE, 0.02)

(95% CI, 0.70–0.77)

2 L on PEM

0.74 (SE, 0.02)

(95% CI, 0.70–0.79)

2 L on DOC

0.66 (SE, 0.04)

(95% CI, 0.58–0.74)

 Chevalier 2013^c [38]

Advanced/metastatic NSCLC

2 L PF

0.70 (0.22)

EQ-5D

French (TTO)

Stage I–Stage III/IV PF and PD

Meets HAS requirements

2 L PD

0.55 (0.35)

 Chouaid 2013 [39]

Advanced/metastatic NSCLC

2 L PF

0.74 (0.18)

(95% CI, 0.68–0.80)

EQ-5D-3 L

UK

At time of advanced diagnosis, mean age 64.8 years

Adenocarcinoma: 65.2%

Large-cell carcinoma: 6.8%

SQ cell carcinoma: 17.1%

Other: 9.9%

Clinical stage at time of survey:

IIIb: 17.9%

IV: 82.1%

Meets NICE requirements

65.0 (19.6)

(95% CI, 59.2–70.8)

EQ-5D VAS

N/A

No

2 L PD

0.59 (0.34)

(95% CI, 0.42–0.77)

EQ-5D-3 L

UK

Meets NICE requirements

53.5 (23.3)

(95% CI, 41.5–65.4)

EQ-5D VAS

N/A

No

 Huang 2016^c [45]

Advanced PD-L1+ NSCLC

2 L PF

0.76 (95% CI, 0.75–0.77)

EQ-5D

NR

Multinational patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapy

Unclear as tariff NR

2 L PD

0.69 (95% CI, 0.66–0.71)

Advanced PD-L1+ NSCLC, 2 L, >  360 days from death

0.81 (0.79, 0.83)

Patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapy

Advanced PD-L1+ NSCLC, 2 L, 180–360 days from death

0.73 (0.71, 0.75)

Advanced PD-L1+ NSCLC, 2 L, 90–180 days from death

0.69 (0.66, 0.72)

Advanced PD-L1+ NSCLC, 2 L, 30–90 days from death

0.60 (0.56, 0.64)

Advanced PD-L1+ NSCLC, 2 L, <  30 days from death

0.40 (0.31, 0.48)

 Iyer 2013 [46]

Advanced/metastatic NSCLC

On treatment: 2 L only

0.53 (0.38)

EQ-5D

UK

French and German patients

Meets NICE and SMC requirements

54.9 (19.3)

EQ-5D VAS

N/A

No

 Langley 2013 [48]

Stage IV NSCLC with brain metastases

NSCLC with BM, previous tx allowed, OSC + WBRT 0 days

0.63

EQ-5D

NR^d

UK and Australian NSCLC patients with brain metastases

No, as VAS tariff used

NSCLC with BM, previous tx allowed, OSC + WBRT 28 days

0.49

NSCLC with BM, previous tx allowed, OSC + WBRT 56 days

0.39

NSCLC with BM, previous tx allowed, OSC + WBRT 112 days

0.36

NSCLC with BM, previous tx allowed, OSC + WBRT 168 days

0.16

NSCLC with BM, previous tx allowed, OSC alone 0 days

0.60

NSCLC with BM, previous tx allowed, OSC alone 28 days

0.49

NSCLC with BM, previous tx allowed, OSC alone 56 days

0.44

NSCLC with BM, previous tx allowed, OSC alone 112 days

0.38

NSCLC with BM, previous tx allowed, OSC alone 168 days

0.36

 Lloyd 2008 [59]

Cancer with chemotherapy-related anaemia or fatigue

Anaemia, Hb level, ≥12.0 g/dL

0.708 (95% CI, 0.057)

SG

N/A

General public sample from UK

No

0.611 (95% CI, 0.112)

TTO

UK cancer patients who have recently experienced chemotherapy-related fatigue and anaemia completing vignette-based TTO

Meets NICE/SMC requirements but still vignette-based health state rather than patient rating own health

 Nafees 2008 [59]

mNSCLC

2 L Stable disease^e

0.65 (SE, 0.02)

SG

N/A

100 members of general public in UK

No, but used in multiple HTA submissions

2 L Responding disease^f

0.67

2 L Response gain

0.02 (SE, 0.01)

2 L Progressive disease^g

0.47

 Novello 2015 [49]

Stage III/IV recurrent NSCLC (SQ and NSQ)^h

2 L NIN + DOC, before treatment (week 0)

0.72

EQ-5D

UK

Multinational patients with stage III/IV recurrent NSCLC (SQ and NSQ) in 2 L after chemotherapy

Adenocarcinoma: 50.1%

Meets NICE/SMC requirements

2 L NIN + DOC, after treatment (week 30)

0.61

2 L PLA + DOC, before treatment (week 0)

0.72

2 L PLA + DOC, after treatment (week 30)

0.62

2 L NIN + DOC, before treatment (week 0)

69.0

EQ-5D VAS

N/A

No

2 L NIN + DOC, after treatment (week 30)

63.2

2 L PLA + DOC, before treatment (week 0)

69.0

2 L PLA + DOC, after treatment (week 30)

63.1

 Reck 2015 [50]

Advanced SQ NSCLC

2 L NIVO at BL

0.68 (0.208)

EQ-5D

NR

Multinational patients with advanced SQ NSCLC

Unclear as tariff NR

2 L DOC at BL

0.66 (0.284)

2 L NIVO at BL

63.7 (18.2)

EQ-5D VAS

N/A

No

2 L DOC at BL

66.3 (20.5)

 Rudell 2016^c [57]

Advanced NSCLC, EGFR+

2 L OSI at BL

65.2 (20.33)

EQ-5D-5 L VAS

N/A

Multinational patients with EGFR+ advanced NSCLC, 2 L after previous TKI

No

2 L OSI at 36 weeks

73.7 (17.33)

 Schuette 2012 [51]

NSCLC Stage IIIB–IV

2 L, PEM at BL

0.66 (0.256)

EQ-5D

UK TTO

Austrian and German advanced/mNSCLC 2 L patients mainly after prior platinum treatment

(IIIa, 6.7%; IIIb, 19.8%;

IV, 73.5%)

Meets NICE/SMC requirements

2 L, PEM at 6 weeks (2nd cycle)

0.02 (0.214)

EQ-5D gain

2 L, PEM at 6th cycle

0.11 (0.228)

2 L, PEM at BL

59.3 (17.8)

EQ-5D VAS

N/A

No

2 L, PEM at 6 weeks (2nd cycle)

3.3 (12.58)

EQ-5D VAS gain

N/A

2 L, PEM at 6th cycle

12.8 (17.62)

 Vargas 2009^c [72]

Advanced NSCLC

2 L, on ERL

0.81

Global QoL index

NR

Patients with advanced NSCLC, 2 L after previous chemotherapy

No

2 L, on taxanes

0.62

 Chen 2010^c [73]

Advanced NSCLC^d

2 L, DOC, during treatment

0.45ⁱ

SG

N/A

UK general public (as algorithm based on Nafees 2008 data used to calculate utilities)

Acceptable data for SMC

2 L, DOC, after treatment

0.57

2 L, PEM, during treatment

0.54

2 L, PEM, after treatment

0.59

3 L, ERL, during treatment

0.48

BSC, during treatment

0.47

 Chevalier 2013 [38]

Advanced/metastatic NSCLC

3/4 L PF

0.61 (0.3)

EQ-5D

French (TTO)

Stage I–Stage III/IV PF and PD

Meets HAS requirements

3/4 L PD

0.42 (0.40)

 Griebsch 2014 [37]

Stage IIIb (with pleural effusion)/IV NSCLC adenocarcinoma

(LUX-LUNG 1)^j

Week 4, progression effect longitudinal model

−0.1

EQ-5D

UK

Multinational advanced/metastatic NSCLC, 2 LL

Meets NICE requirements

Mixed effect longitudinal model IRC

−0.056 (95% CI,

− 0.083 to − 0.028)

Mixed effect longitudinal model IN

−0.065 (95% CI,

− 0.092 to − 0.039)

Mixed effect longitudinal model IRC, AFA

−0.06

Mixed effect longitudinal model IRC, BSC

−0.046

Mixed effect longitudinal model IINV, AFA

−0.081

Mixed effect longitudinal model IINV, BSC

−0.033

Week 4, progression effect longitudinal model

−7.3

EQ-5D VAS

N/A

No

Mixed effect longitudinal model IRC

−3.76 (95% CI, −5.19 to −2.32)

Mixed effect longitudinal model INV

− 3.83 (95% CI, − 5.21 to − 2.44)

Mixed effect longitudinal model IRC, AFA

3.63

Mixed effect longitudinal model IRC, BSC

−4.11

Mixed effect longitudinal model INV, AFA

−4.42

Mixed effect longitudinal model INV, BSC

−2.55

 Hirsh 2013 [40]

Stage IIIB/IV NSCLC

3 LL on AFA + BSC

0.71

EQ-5D

UK

98% adenocarcinoma

PD following treatment lines

1–2, one of which was platinum based, plus PD after at least 12 weeks of ERL or GEF

Meets NICE requirements

3 LL on PLA + BSC

0.67

3 LL on AFA + BSC

67.4

EQ-5D VAS

N/A

No

3 LL on PLA + BSC

65.2

 Schwartzberg^c 2015 [60]

Stage IIIb/IV NSCLC (SQ & NSQ)

All patients wk 6

1.0 (21.7)

EQ-5D VAS

N/A

Patients, 2 LL, NIVO 3 mg/kg i.v. q2w

No

wk 12

5.8 (21.3)

wk 18

8.2 (22.3)

wk 24

8.2 (23.9)

wk 30

8.4 (29.2)

SDis wk 6

3.8 (19.8)

wk 12

6.4 (21.9)

wk 18

8.2 (20.9)

wk 24

5.2(21.9)

wk 30

7.2 (28.5)

PR wk 6

7.3 (22.4)

wk 12

6.6 (24.7)

wk 18

8.1 (27.6)

wk 24

18.1 (31.0)

wk 30

13.7 (38.2)

PD wk 6

−5.8 (21.1)

wk 12

−3.0 (19.8)

wk 18

3.9 (24.3)

wk 24

6.8 (12.2)

wk 30

5.5 (15.7)

 Bradbury 2008^c [42]

Advanced NSCLC

On ERL

0.772

EQ-5D

NR (possibly Canadian)

Canadian patients

Potentially relevant to CADTH

On BSC

0.754

 Chang 2016^c [63]

Advanced NSCLC

> 360 days from death

0.904

(95% CI, 0.892–0.917)

TTO

NR

General public, South Korea

No

180–360 days from death

0.720

(95% CI, 0.692–0.748)

90–180 days from death

0.627

(95% CI, 0.598–0.655)

30–90 days from death

0.379

(95% CI, 0.349–0.409)

< 30 days from death

0.195

(95% CI, 0.172–0.218)

 Dansk 2016^c [43]

Advanced NSCLC

Synthesized PF

Median, 0.706

Range, 0.620–0.815

Synthesized utility across > 1 instrument type

NR

Utilities synthesized included those where respondents were patients and those where they were the general public considering a hypothetical health state

No

Synthesized PF trial-based

Median, 0.750

Range, 0.627–0.815

Synthesized PF non-trial-based

Median, 0.653

Range, 0.620–0.653

Synthesized PD

Median, 0.565

Range, 0.470–0.688

Synthesized PD trial-based

Median, 0.599

Range, 0.550–0.688

Synthesized PD non-trial-based

Median, 0.473

Range, 0.470–0.530

 Doyle 2008 [65]

Metastatic NSCLC

SDis, no additional symptoms

0.626

SG

N/A

General public

No

Treatment response, no additional symptoms

0.712

 Grunberg 2009^c [58]

BC/LC

Chemotherapy-induced nausea and vomiting of differing severity

Reported graphically

SG

N/A

Patients BC/LC

Meets NICE requirements

 Grutters 2010^c [44]

NSCLC (stage unspecified)

NSCLC with grade 3+ dyspnoea, stage unspecified

Median, 0.52

EQ-5D-5 L

NR

Patients at an early treatment stage

No

 Jang 2010 [47]

Stage IV NSCLC

Stage IV NSCLC

0.75 (0.15)

EQ-5D

US

Patients with NSCLC attending a major Canadian cancer center outpatient clinic

No

 Linnet 2015^c [62]

Stage IV NSCLC on oral VINO

PCS, cycle 2

37.0

SF-12

N/A

Patients

No

PCS, cycle 3

38.6

MCS, cycle 2

47.7

MCS, cycle 3

44.2

PCS, cycle 2

52.9

Caregivers

Potential to estimate SF-6D for caregivers to mNSCLC patients, for SMC or CADTH

PCS, cycle 3

53.4

MCS, cycle 2

46.2

MCS, cycle 3

44.6

 Lloyd 2005^c [66]

Stage IV NSCLC

RES

0.70

SG^k

N/A

General public

No

SDis, oral treatment

0.63

SDis, i.v. treatment

0.58

PD

0.42

End of life

0.33

 Manser 2006 [61]

Stage IV NSCLC

Stage IV

Median, 0.68

(IQR, 0.54–0.82)

AQoL

Australia

Mixed stage enrolled:

I, 31.5%; II, 17.4%; IIIa, 16.3%; IIIb, 7.6%; IV, 25.0%

No

 Matza 2014 [67]

Stage IV cancer with bone metastases

Cancer with bone metastases and no SRE

0.47 (0.41)

TTO

N/A

General public, UK

(Edinburgh and London)

No

0.47 (0.45)

General public, Canada

(Montreal and Toronto)

0.47 (0.42)

General public, UK and Canada

 Stewart 2015 [56]

EGFR+ Stage IV NSCLC

PR/SDis on EGFR TKIs (GEF, ERL, AZD9291)

0.82 (SE, 0.16)

EQ-5D-3 L

NR

Patients, eligible for or on TKI tx, 55% Asian, 45% male, median age 60, 66% never smokers. Stage IV:

at diagnosis, 80%

when surveyed, 100%

Unclear

Responded to standard chemotherapy

0.80 (SE, 0.12)

EGFR+, responded to GEF

0.84 (SE, 0.14)

EGFR+, responded to ERL

0.82 (SE, 0.17)

EGFR+, responded to AZD9291

0.83 (SE, 0.16)

EGFR+, PD during TKI treatment (GEF, ERL, AZD9291)

0.74 (SE, 0.08)

EGFR+, all patients (PR/SDis/PD), 25% 3LL

0.802

 Tabberer 2006 [52]

Advanced NSCLC

RES

0.49

EQ-5D

NR

General public, UK

(Cardiff, Glasgow, London and Oxford)

No

SDis

0.46

SDis + oral treatment

0.45

SDis + i.v. treatment

0.43

PD

0.22

Near death

0.15

 Trippoli 2001 [53]

Metastatic NSCLC

Metastatic NSCLC

0.53 (0.36)

EQ-5D

UK (TTO)

Italian patients

Meets NICE and SMC reference cases

0.55 (0.22)^l

EQ-5D VAS

N/A

No

 Yang 2014 [54]

Stage IIIB/IV NSCLC

Stage IV inoperable, performance status 0–1

0.75 (0.22)

EQ-5D

Taiwan

Patients, mixed NSCLC stages: I, 0.8%; II, 0%; IIIA, 4.5%; IIIB, 16.9%; IV, 77.8%

No

Stage IV inoperable, performance status 0–4

0.75 (0.22)

 Yokoyama 2013^c [55]

Advanced NSCLC/SCLC

Stage IIIB/IV NSCLC/SCLC with bone metastasis and SRE

NR

EQ-5D

NR

Patients, advanced NSCLC, 72%, SCLC, 28%

NSCLC and SCLC: IIIB, 37%; IV, 63%

No